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OBJECTIVE: The role of chemotherapy in treating advanced thymic carcinoma is unclear. The purpose of the
current study was to investigate the efficacy of chemotherapy and the prognostic factors for patients with
advanced thymic carcinoma.
METHODS: A retrospective review of the medical records of 86 patients treated with chemotherapy for
advanced thymic carcinoma was conducted between 2000 and 2012 at our institution. The clinical
characteristics, chemotherapy regimens and prognostic factors were analyzed. Survival curves were plotted
using the Kaplan–Meier method and the Cox proportional hazard model was used for multivariate analysis.
RESULTS: Of the 86 patients, 56 were male and 30 were female. The median survival time was 24.5 months. For
the first-line chemotherapy treatment, the objective response rate was 47.7% and the disease control rate was
80.2%. The median progression-free survival for all patients was 6.5 months for first-line chemotherapy. No
significant differences in progression-free survival were observed among the different chemotherapy regimens.
Multivariate analyses revealed that the prognostic factors for overall survival included performance status
(p=0.043), histology grade (p=0.048), and liver metastasis (p=0.047).
CONCLUSION: Our results suggest that there is no difference in efficacy between multiagent and doublet
regimens. The prognosis of patients with advanced thymic carcinoma can be predicted based on histological
grade, liver metastasis and performance status.
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’ INTRODUCTION
Thymic epithelial tumors are the most common anterior
mediastinal neoplasm (1). According to worldwide cancer
statistics, these tumors are relatively uncommon, with a low
incidence of approximately 1.3/1,000,000 people (2). Accord-
ing to the histological criteria published by the World Health
Organization (WHO) in 2004, they are classified into two
histopathological types: thymoma and thymic carcinomas.
Thymic carcinomas are rare, invasive thymic epithelial
tumors associated with a poor prognosis. Surgery is the main
therapeutic modality for early-stage patients (3). For people
with advanced-stage thymic carcinoma, complete surgical
resection is typically not possible, and the only treatment
option is palliative chemotherapy or radiochemotherapy (4).
Despite the 40–60% response rate to first-line chemotherapy
of patients with advanced thymic carcinoma, most of these
patients relapse within one year of initial treatment and the
majority eventually die due to disease progression.
Because of the rarity of this cancer, published findings
regarding the efficacy and toxicity of chemotherapy are
limited. Knowledge regarding chemotherapy for thymic
carcinoma has mainly been based on retrospective series
with small patient samples, although several prospective
trials have also been conducted (4). Several studies have
described palliative chemotherapy regimens, but because no
randomized controlled studies have been performed, it is
unclear which regimen is the most effective.
Our current study reviewed a series of consecutive
patients with advanced thymic carcinoma who had been
treated at a single institution to evaluate the efficacies of
various regimens. The prognostic factors for advanced
thymic carcinoma were also determined.
’ MATERIALS AND METHODS
Patient eligibility
Patients with pathological stage IV (including IVa and IVb)
thymic carcinoma who had undergone treatment at Zhejiang
Cancer Hospital between January 2000 and December 2012
were retrospectively identified. The study was approved by
the Ethics Committee of Zhejiang Cancer Hospital.DOI: 10.6061/clinics/2015(12)03
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Two pathologists who were blinded to the patients’ clinical
and pathological data reviewed all of the samples. The histologic
types were determined based on the 2004 WHO classification
(5). Patients’ clinical stages were determined according to the
Masaoka-Koga staging system (6). Histological findings were
classified as low-grade (squamous cell, mucoepidermoid, and
basaloid carcinomas) or high-grade (lymphoepithelioma-like,
neuroendocrine, clear cell, sarcomatoid and undifferentiated
carcinomas) according to Suster and Rosai (7). Recurrence or
metastasis was confirmed by chest CT, bone scan and abdomen
CT. Patients who died from another disease not related to
thymic carcinoma were excluded from the current study.
Response evaluation and statistical analysis
The Response Evaluation Criteria in Solid Tumors (RECIST
1.1) system was used to evaluate tumor responses. Objective
tumor responses included complete response (CR), partial
response (PR), stable disease (SD) and progressive disease
(PD). The disease control rate (DCR) was defined as the sum of
the objective responses and stabilization rates (CR+PR+SD).
Progression-free survival (PFS) encompassed the time from
the first cycle of chemotherapy to the time of documented
progression or death. Survival was recorded from the first day
of treatment to the date of death or that of the last follow-up
visit. Survival curves were calculated using the Kaplan–Meier
method. Multivariate analysis was performed using the Cox
regression model. Statistical analysis was performed with SPSS
17 software (Inc., Chicago, IL). A po0.05 was considered
significant. The last follow-up time point was Jan 31, 2014.
’ RESULTS
Patient characteristics
A total of 86 patients who met our criteria were identified,
and the patient characteristics are listed in Table 1. The study
population consisted of 56 men and 30 women, with a median
age at diagnosis of 48 years (range of 31-79). At enrollment,
47 patients (54.7%) had stage IVa disease and 39 (43.3%) had
stage IVb disease. Histologic examination revealed the follow-
ing subtypes of thymic carcinoma: 52 patients (60.5%) had
squamous cell carcinoma, 13 (15.1%) had undifferentiated
carcinoma, 7 (8.1%) had neuroendocrine carcinoma, 4 (4.7%)
had small cell carcinoma, 3 (3.5%) had mucoepidermoid
carcinoma and 7 (8.1%) had carcinoma of another subtype.
Among the 86 patients, an Eastern Cooperative Oncology
Group performance status (PS) of 0–1 was observed in
74 patients (86.0%) and PS 2 (14.0%) was observed in 12 patients.
At the time of treatment, the most common sites of
metastasis included the lymph nodes (22 patients, 25.6%),
lung (20 patients, 23.3%), liver (14 patients, 16.3%), bone
(12 patients, 14.0%) and others (20.8%).
Chemotherapy regimens
The first-line chemotherapy regimens used are shown in
Table 1. The distribution of these regimens was as follows:
7 patients (8.1%) received ADOC (cisplatin, doxorubicin,
vincristine and cyclophosphamide); 17 (19.8%) received CAP
(cyclophosphamide, doxorubicin, and cisplatin); 12 (14.0%)
received VIP (etoposide, ifosfamide and cisplatin); 43 (50.0%)
received carboplatin or cisplatin-based doublet chemotherapy
(including paclitaxel, gemcitabine, vinorelbine, cyclophospha-
mide and docetaxel); and 7 (8.1%) received a single agent.
Forty-two patients (48.9%) received second-line or greater
chemotherapy. The most common regimen was docetaxel-based
chemotherapy, which was administered to 16 patients, followed
by paclitaxel-based chemotherapy.
Efficacy analysis of first-line chemotherapy
regimens
The median follow-up period was 31.5 (5.5-125.0) months.
For first-line chemotherapy, 41 patients exhibited a PR
(47.7%), 28 showed SD (32.6%) and 17 exhibited PD. There
were no complete responders. The response rate for the
patients treated with ADOC chemotherapy (n=7) was 42.9%
and it was 51.7% for those treated with triplet (CAP and VIP)
chemotherapy (n=29), 48.8% for those treated with platinum-
based doublet chemotherapy (n=43), and 28.6% for those
who received single-agent chemotherapy (n=7) (Table 2).
The median PFS for all patients was 6.5 months. The PFS
values for the ADOC regimen and triplet, doublet and
single-agent groups were 7.5 months, 6.6 months, 6.6 months
and 2.3 months, respectively (p=0.193) (Figure 1). The
median survival time for all patients was 24.1 months (range
of 6.5-125 months). The OS values for the ADOC, triplet,
doublet and single-agent groups were 27.5 months, 25.4
months, 20.8 months and 8.2 months, respectively (p=0.201)
(Figure 2).
Table 1 - Demographic characteristics of the study population.
Number (%)
Gender
Male 56(65.1)
Female 30(34.9)
Age
Range 31-79
Median 48
o50 52(60.5)
X50 34(39.5)
Smoking status
Never 32(37.2)
Former/current 54(62.8)
Stage
IVa 47(54.7)
IVb 39(45.3)
Liver metastasis
Yes 14(19.4)
No 72(80.6)
PS
0-1 74(86.0)
2-3 12(14.0)
Histology
Low-grade 55(64.0)
Squamous cell carcinoma 52(60.0)
Mucoepidermoid carcinoma 3(4.0)
High-grade 31(36)
Undifferentiated carcinoma 13(15.1)
Neuroendocrine carcinomas 7(8.1)
Small cell carcinoma 4(4.7)
Others 7(8.1)
First-line chemotherapy
ADOC 7(8.1)
Triplet chemotherapies 29(33.7)
Double regimens 43(50.0)
Cisplatin-containing 25(29.1)
Carboplatin-containing 18(20.9)
Single-agent 7(8.1)
Further-line chemotherapy
Yes 42(48.8)
No 44(51.2)
ADOC: cisplatin, doxorubicin, vincristine and cyclophosphamide
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Univariate and Cox regression analyses
Univariate analyses were performed using the Kaplan–
Meier method to assess the predictive capacity of each
variable for the determination of OS and the data are
summarized in Table 3. Gender, age, cancer stage, che-
motherapy regimen and smoking status were not found to be
significantly associated with OS. PS (p=0.002), histology
grade (p=0.020), liver metastasis (p=0.001, Figure 3) and the
response to first-line chemotherapy (p=0.047) were predictive
of OS.
A multivariate Cox regression model was constructed with
the incorporation of PS, histology grade, the response to first-
line chemotherapy, cancer stage and liver metastasis to evaluate
OS. PS (p=0.043), histology grade (p=0.048) and liver metastasis
(p=0.047) remained as independent prognostic factors, but
cancer stage (p=0.255) and the response to first-line chemother-
apy (p=0.677) did not have significant influences on survival
based on multivariate analysis (Table 4).
’ DISCUSSION
To the best of our knowledge, this is the largest study
evaluating the efficacy of chemotherapy and prognostic
factors for advanced thymic carcinoma. Our results suggest
that there are no differences in efficacy among the different
regimens used to treat advanced thymic carcinoma. Liver
metastasis, poor PS and high-grade histology indicated a
worse prognosis.
There is still no consensus on the optimal chemotherapy
regimen for advanced thymic carcinoma. Previous studies
have shown that multiagent chemotherapy plays an impor-
tant role in advanced thymic carcinoma (8). Anthracycline-
based regimens, such as CAP and ADOC, are widely used
and are recommended as standard first-line treatments of
advanced thymic carcinoma according to the NCCN guide-
lines. However, the cardiac toxicity of anthracycline-based
regimens is an important consideration in clinical practice
(9,10). Non-anthracycline regimens are preferable to mini-
mize potential cardiac toxicity.
The use of platinum-based doublet chemotherapy as first-
line chemotherapy has been shown to be efficacious. Regi-
mens such as TC (carboplatin and paclitaxel) and AC
(amrubicin and carboplatin) have also been shown to be
effective based on studies with small sample sizes (11-15).
However, no prospective or retrospective study has com-
pared the efficacies of multiagent and doublet chemotherapy
in the treatment of this rare carcinoma. No differences in PFS
or OS among the different regimens were observed in the
current study; however, the frequency of toxicity was much
lower for doublet chemotherapy compared with multiagent
chemotherapy (the frequencies of grades 3/4 toxicity were
65.1% and 86.1%, respectively, p=0.06).
Table 2 - The efficacy of different regimens.
Efficacy ADOC (n=7) Triplet (n=29) Doublet (n=43) Single-agent (n=7)
Complete response 0 0 0 0
Partial response 3 15 21 2
Stable disease 3 9 13 1
Progressive disease 1 5 9 4
Response rate 42.90% 51.70% 48.80% 28.60%
Disease control rate 85.70% 82.80% 79.10% 42.90%
Median progression-free survival 7.5 months 6.6 months 6.6 months 2.3 months
Median overall survival 27.5 months 25.4 months 20.8 months 8.2 months
Figure 1 - Kaplan–Meier curves comparing PFS in patients treated with various first-line chemotherapy regimens.
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Few studies have been conducted to identify the prognostic
factors for advanced thymic carcinoma. Histologic grade was
found to be a significant prognostic factor for overall survival
by Hosaka et al. (16), but no statistically significant difference
was observed between low- and high-grade histology groups
in another study (17). However, in the present study,
a significant difference in OS between the low-grade and
high-grade histology groups was observed. A retrospective
Figure 2 - Kaplan–Meier curves comparing OS in patients treated with various first-line chemotherapy regimens.
Table 3 - Univariate analysis of the patient survival according to the clinicopathologic characteristics.
Median PFS p Median OS p
Gender 0.650 0.722
Male 6.5 24.3
Female 5.5 24.1
Age 0.059 0.749
o50 6.6 24.2
X50 5.5 18.9
Smoking status 0.785 0.895
Never 6.6 24.2
Former/current 6.5 20.8
Stage 0.126
IVa 7.5
IVb 5.5
PS 0.019 0.002
0-1 6.8 24.8
2-3 2.3 9.3
Histology 0.023 0.020
Low-grade 7.5 25.4
High-grade 4.3 14.5
Liver metastasis 0.013 0.001
Yes 2.4 10.8
No 6.8 25.4
First-line chemotherapy 0.193 0.201
ADOC 7.5 27.5
Triplet 6.6 25.4
Double regimens 6.6 20.8
Single-agent 2.3 8.2
Further-line chemotherapy 0.725 0.042
Yes 6.4 27.6
No 6.6 20.8
Response to first-line chemotherapy 0.014 0.047
Yes 8.2 28.5
No 4.2 21.5
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study conducted by Okuma et al. (17), which included 40
advanced thymic carcinoma patients, demonstrated that the
response to first-line chemotherapy was the only factor
associated with a significantly better prognosis. In contrast,
this response was not found to be a significant prognostic
factor based on multivariate analysis in the current study.
Our results showed that liver metastasis was a poor prog-
nostic factor for advanced thymic carcinoma, consistent with
other solid carcinomas (18).
Recent studies have focused on the role of targeted therapy in
advanced thymic carcinoma. c-KIT expression has been demon-
strated to be common in thymic carcinomas. Several case reports
have documented clinical responses to treatment with sunitinib
and sorafenib (19-20). Recently, Rajan et al. (21) have shown that
cixutumumab, a fully human IgG1 monoclonal antibody that
targets insulin-like growth factor 1 receptor and is used as a
mono-therapy, is well tolerated and is active in patients with
relapsed thymoma but not in those with thymic carcinoma.
The major limitations of the present study are its retro-
spective nature and the heterogeneity of the chemotherapy
regimens evaluated. However, it provides relevant insights
into the efficacies of different treatments of advanced thymic
carcinoma as one of the largest reports to date focusing on
treatment regimens for this rare tumor type.
The results of this study suggest that there is no difference
in efficacy between multiagent and doublet regimens (the
p values for PFS and OS were 0.93 and 0.63, respectively).
The prognosis of advanced thymic carcinoma can be predicted
based on histological findings, liver metastasis and PS.
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